These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37083719)

  • 21. Landscape and Construction of a Novel N6-methyladenosine-related LncRNAs in Cervical Cancer.
    Liu X; Zhang W; Wan J; Xiao D; Wei M
    Reprod Sci; 2023 Mar; 30(3):903-913. PubMed ID: 36074248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
    Front Oncol; 2022; 12():774307. PubMed ID: 35141159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
    Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
    Front Genet; 2021; 12():726369. PubMed ID: 34721523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
    Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
    J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
    Li Y; Li X; Yu Z
    Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.
    Liu J; Zhang W; Wang J; Lv Z; Xia H; Zhang Z; Zhang Y; Wang J
    J Cancer Res Clin Oncol; 2023 May; 149(5):1969-1983. PubMed ID: 35731271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential Prognostic Value of a Seven m6A-Related LncRNAs Signature and the Correlative Immune Infiltration in Colon Adenocarcinoma.
    Chai XK; Qi W; Zou CY; He CX; Su M; Zhao DQ
    Front Genet; 2021; 12():774010. PubMed ID: 35003214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic signature analysis and survival prediction of esophageal cancer based on N6-methyladenosine associated lncRNAs.
    He T; Gao Z; Lin L; Zhang X; Zou Q
    Brief Funct Genomics; 2024 May; 23(3):239-248. PubMed ID: 37465899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma.
    Weng C; Wang L; Liu G; Guan M; Lu L
    Front Oncol; 2021; 11():763027. PubMed ID: 34868980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma.
    Zhou X; Zhang H; Duan Y; Zhu J; Dai H
    J Clin Lab Anal; 2023 Jan; 37(1):e24813. PubMed ID: 36525280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the prognostic significance and potential mechanisms of lncRNAs associated with m6A methylation in papillary thyroid carcinoma.
    Huang Y; Li X; Chen W; He Y; Wu S; Li X; Hou B; Wang S; He Y; Jiang H; Lun Y; Zhang J
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108286. PubMed ID: 34735975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
    Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
    Front Oncol; 2021; 11():710767. PubMed ID: 34458149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis and prognostic significance of tumour immune infiltrates and immune microenvironment of m6A-related lncRNAs in patients with gastric cancer.
    Huang J; Song J; Li X; Liu S; Huang W; Shen Z; Cheng Y; Kou S; Gao Z; Tian Y; Hu J
    BMC Med Genomics; 2022 Jul; 15(1):164. PubMed ID: 35879790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.
    Nie X; Tan J
    Hereditas; 2022 Mar; 159(1):17. PubMed ID: 35303965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.